

Author index (Vol. 104)

- Abate, N., Vega, G.L. and Grundy, S.M.
Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100 (104) 159
- Abbott, C., see Mackness, M.I. (104) 129
- Achard, F., see Bénistant, C. (104) 27
- Almario, R.U., see Kasim, S.E. (104) 147
- Arrol, S., see Mackness, M.I. (104) 129
- Aubó, C., see Pedro-Botet, J. (104) 87
- Auclair, M., see Mazière, J.-C. (104) 213
- Auguet, T., see Pedro-Botet, J. (104) 87
- Bagdade, J.D., Lane, J.T., Subbaiah, P.V., Otto, M.E. and Ritter, M.C.
Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus (104) 69
- Bellosta, S., see Bernini, F. (104) 19
- Bénistant, C., Achard, F., Marcelon, G. and Lagarde, M.
Platelet inhibitory functions of aortic endothelial cells. Effects of eicosapentaenoic and docosahexaenoic acids (104) 27
- Berenson, G.S., see Freedman, D.S. (104) 37
- Bernini, F., Didoni, G., Bonfadini, G., Bellosta, S. and Fumagalli, R.
Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages (104) 19
- Bonfadini, G., see Bernini, F. (104) 19
- Bonithon-Kopp, C., Levenson, J., Scarabin, P.-Y., Guillauneuf, M.-T., Kirzin, J.-M., Malmejac, A. and Guize, L.
Longitudinal associations between plasma viscosity and cardiovascular risk factors in a middle-aged French population (104) 173
- Byers, T., see Freedman, D.S. (104) 37
- Chapman, M.J., see Guérin, M. (104) 195
- Ciccarelli, R., see Porreca, E. (104) 137
- Cohen, J., see Moliterno, D.J. (104) 223
- Cordopatri, F.
A possible protective role of veins against atherosclerosis (104) 221
- Cuccurullo, F., see Porreca, E. (104) 137
- de Wit, E., see Lombardi, P. (104) 117
- Di Febbo, C., see Porreca, E. (104) 137
- Didoni, G., see Bernini, F. (104) 19
- Dolphin, P.J., see Guérin, M. (104) 195
- Durrington, P.N., see Mackness, M.I. (104) 129
- Ehnholm, C., see Tervahauta, M. (104) 47
- Elovson, J., see Kasim, S.E. (104) 147
- Farhat, M.H.B., see Slimane, M.N. (104) 153
- Frants, R.R., see Lombardi, P. (104) 117
- Freedman, D.S., Wattigney, W.A., Srinivasan, S., Newman, W.P., III, Tracy, R.E., Byers, T. and Berenson, G.S.
The relation of atherosclerotic lesions to antemortem and postmortem lipid levels: the Bogalusa Heart Study (104) 37
- Friedman, M.H. and Fry, D.L.
Arterial permeability dynamics and vascular disease (104) 189
- Fry, D.L., see Friedman, M.H. (104) 189
- Fumagalli, R., see Bernini, F. (104) 19
- Grundy, S.M., see Abate, N. (104) 159
- Guérin, M., Dolphin, P.J. and Chapman, M.J.
Familial lecithin:cholesterol acyltransferase deficiency: further resolution of lipoprotein particle heterogeneity in the low density interval (104) 195
- Guillauneuf, M.-T., see Bonithon-Kopp, C. (104) 173
- Guize, L., see Bonithon-Kopp, C. (104) 173
- Haigle, J., see Mazière, J.-C. (104) 213
- Hammami, M., see Slimane, M.N. (104) 153
- Havekes, L.M., see Lombardi, P. (104) 117
- Hayashi, K., Nakashima, K., Saeki, M., Kurushima, H., Kurokawa, J.-I., Kuga, Y., Nomura, S.-I., Ohkura, Y., Ohtani, H., Tanaka, K. and Kajiyama, G.
Identification of a functional receptor differing from the LDL receptor that catabolizes chylomicron remnant in Hep G2 cells (104) 105
- Hoffer, M.J.V., see Lombardi, P. (104) 117
- Ikeda, M., see Ikeda, U. (104) 61
- Ikeda, U., Ikeda, M., Seino, Y., Takahashi, M., Kasahara, T., Kano, S. and Shimada, K.
Expression of intercellular adhesion molecule-1 on rat vascular smooth muscle cells by pro-inflammatory cytokines (104) 61
- Janus, E.D., see Lam, K.S.L. (104) 183

- Jauhiainen, M., see Tervahauta, M. (104) 47
 Jen, K.-L.C., see Kasim, S.E. (104) 147
 Jessen, M.E., see Moliterno, D.J. (104) 223
- Kajiyama, G., see Hayashi, K. (104) 105
 Kano, S., see Ikeda, U. (104) 61
 Kasahara, T., see Ikeda, U. (104) 61
 Kasim, S.E., Elovson, J., Khilnani, S., Almario, R.U. and Jen, K.-L.C.
 Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat (104) 147
 Khilnani, S., see Kasim, S.E. (104) 147
 Kirzin, J.-M., see Bonithon-Kopp, C. (104) 173
 Kivinen, P., see Tervahauta, M. (104) 47
 Kuga, Y., see Hayashi, K. (104) 105
 Kung, A.W.C., see Lam, K.S.L. (104) 183
 Kurokawa, J.-I., see Hayashi, K. (104) 105
 Kurushima, H., see Hayashi, K. (104) 105
- Lagarde, M., see Bénistant, C. (104) 27
 Lam, K.S.L., Pang, R.W.C., Janus, E.D., Kung, A.W.C. and Wang, C.C.L.
 Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly (104) 183
 Lane, J.T., see Bagdade, J.D. (104) 69
 Leuven, J.A.G., see Lombardi, P. (104) 117
 Levenson, J., see Bonithon-Kopp, C. (104) 173
 Lombardi, P., Hoffer, M.J.V., Top, B., de Wit, E., Leuven, J.A.G., Frants, R.R. and Havekes, L.M.
 An acceptor splice site mutation in intron 16 of the low density lipoprotein receptor gene leads to an elongated, internalization defective receptor (104) 117
- Maatoug, F., see Slimane, M.N. (104) 153
 Mackness, M.I., Arrol, S., Abbott, C. and Durrington, P.N.
 Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase (104) 129
 Malmejac, A., see Bonithon-Kopp, C. (104) 173
 Marcelon, G., see Bénistant, C. (104) 27
 Mazière, C., see Mazière, J.-C. (104) 213
 Mazière, J.-C., Myara, I., Salmon, S., Auclair, M., Haigle, J., Santus, R. and Mazière, C.
 Copper and malondialdehyde-induced modification of high density lipoprotein and parallel loss of lecithin cholesterol acyltransferase activation (104) 213
 Mittelman, A., see Vlasic, N. (104) 79
 Moliterno, D.J., Jessen, M.E., Schueler, K. and Cohen, J.
 Plasma lipoprotein(a) concentrations are not elevated by cardiopulmonary bypass (104) 223
 Myant, N.B.
 Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia (104) 1
 Myara, I., see Mazière, J.-C. (104) 213
- Nakashima, K., see Hayashi, K. (104) 105
 Newman, W.P., III, see Freedman, D.S. (104) 37
 Nissinen, A., see Tervahauta, M. (104) 47
 Nogués, X., see Pedro-Botet, J. (104) 87
 Nomura, S.-I., see Hayashi, K. (104) 105
- Ohkura, Y., see Hayashi, K. (104) 105
 Ohtani, H., see Hayashi, K. (104) 105
 Otto, M.E., see Bagdade, J.D. (104) 69
- Pang, R.W.C., see Lam, K.S.L. (104) 183
 Pedro-Botet, J., Sentí, M., Auguet, T., Nogués, X., Rubiés-Prat, J., Aubó, C. and Vidal-Barraquer, F.
 Apolipoprotein(a) genetic polymorphism and serum lipoprotein(a) concentration in patients with peripheral vascular disease (104) 87
 Pekkanen, J., see Tervahauta, M. (104) 47
 Porreca, E., Ciccarelli, R., Di Febbo, C. and Cuccurullo, F.
 Protein kinase C pathway and proliferative responses of aged and young rat vascular smooth muscle cells (104) 137
 Pousse, H., see Slimane, M.N. (104) 153
- Ramos, L., see Vlasic, N. (104) 79
 Ritter, M.C., see Bagdade, J.D. (104) 69
 Rubiés-Prat, J., see Pedro-Botet, J. (104) 87
- Saeki, M., see Hayashi, K. (104) 105
 Saito, J., see Shiina, T. (104) 95
 Salmon, S., see Mazière, J.-C. (104) 213
 Santus, R., see Mazière, J.-C. (104) 213
 Scarabin, P.-Y., see Bonithon-Kopp, C. (104) 173
 Schueler, K., see Moliterno, D.J. (104) 223
 Seino, Y., see Ikeda, U. (104) 61
 Sentí, M., see Pedro-Botet, J. (104) 87
 Shiina, T., Terano, T., Saito, J., Tamura, Y. and Yoshida, S.
 Eicosapentaenoic acid and docosahexaenoic acid suppress the proliferation of vascular smooth muscle cells (104) 95
 Shimada, K., see Ikeda, U. (104) 61
 Slimane, M.N., Pousse, H., Maatoug, F., Hammami, M. and Farhat, M.H.B.
 Phenotypic expression of familial hypercholesterolaemia in Central and Southern Tunisia (104) 153
 Srinivasan, S., see Freedman, D.S. (104) 37
 Stemerman, M.B., see Vlasic, N. (104) 79
 Stengård, J., see Tervahauta, M. (104) 47
 Subbaiah, P.V., see Bagdade, J.D. (104) 69
- Takahashi, M., see Ikeda, U. (104) 61
 Tamura, Y., see Shiina, T. (104) 95
 Tanaka, K., see Hayashi, K. (104) 105
 Terano, T., see Shiina, T. (104) 95
 Tervahauta, M., Pekkanen, J., Kivinen, P., Stengård, J., Jauhiainen, M., Ehnholm, C. and Nissinen, A.
 Prevalence of coronary heart disease and associated risk factors among elderly Finnish men in the Seven Countries Study (104) 47

Top, B., see Lombardi, P. (104) 117

Tracy, R.E., see Freedman, D.S. (104) 37

Vega, G.L., see Abate, N. (104) 159

Vidal-Barraquer, F., see Pedro-Botet, J. (104) 87

Vlasic, N., Ramos, L., Mittelman, A. and Stemerman, M.B.
Inhibition of smooth muscle cell proliferation and DNA

synthesis by Vasoprin — a biological response modifier
(104) 79

Wang, C.C.L., see Lam, K.S.L. (104) 183

Wattigney, W.A., see Freedman, D.S. (104) 37

Yoshida, S., see Shiina, T. (104) 95

Subject index (Vol. 104)

- Acromegaly, (104) 183
 Acyl-CoA, (104) 19
 Adaptation, (104) 189
 Aging, (104) 137
 Antibody MB19, (104) 1
 Anti-proliferative effect, (104) 95
 Apolipoprotein(a), (104) 183
 Apolipoprotein A-I, (104) 195
 Apolipoprotein B, (104) 195
 Apolipoprotein B-100, (104) 1, 159
 Apolipoproteins, (104) 47, 153
 Arterial permeability, (104) 189
 Atherogenesis, (104) 137, 189
 Atherosclerosis, (104) 221

 Biologic response modifier, (104) 79
 Blood coagulation factors, (104) 47
 Blood pressure, (104) 47

 Cardiopulmonary bypass, (104) 223
 Cardiovascular disease, (104) 47
 Cardiovascular risk factors, (104) 173
 Carotid arteries, (104) 221
 Children, (104) 37
 Cholesterol, (104) 37, 47, 159
 Cholesterol acyltransferase, (104) 19
 Cholesteryl ester, (104) 19
 Cholesteryl ester transfer, (104) 69
 Cholestyramine, (104) 1
 Chylomicron remnant, (104) 105
 Copper ions, (104) 213
 Coronary artery disease, (104) 1
 Coronary heart disease, (104) 47
 Countercurrent heat exchange, (104) 221

 Denaturing gradient gel electrophoresis, (104) 117
 Diurnal changes, (104) 189
 DNA specific activity, (104) 79
 Docosahexaenoic acid, (104) 27, 95
 Duplex scanning, (104) 221

 Eicosapentaenoic acid, (104) 27, 95
 Endothelium, (104) 27
 Epidemiology, (104) 173

 Familial defective apo B-100, (104) 1
 Familial hypercholesterolaemia, (104) 1, 117, 153
 Fatty streaks, (104) 37
 Fibrous plaques, (104) 37

 Growth hormone, (104) 183

 HDL modification, (104) 213
 Hemodynamics, (104) 189
 Hemorheology, (104) 173
 Hep G2 cells, (104) 105
 Heparin affinity chromatography, (104) 195
 High density lipoprotein, (104) 129
 HMG-CoA reductase inhibitors, (104) 19, 147
 3-Hydroxy-3-methylglutaryl coenzyme A, (104) 19

 ImuVert, (104) 79
 Intercellular adhesion molecule-1, (104) 61
 Interleukin 1, (104) 61
 Interleukin 6, (104) 61

 LDL, (104) 159
 LDL patterns, (104) 159
 LDL receptor-related protein (LRP), (104) 105
 Lecithin cholesterol acyltransferase, (104) 213
 Lipid peroxides, (104) 95, 129
 Lipoprotein(a), (104) 1, 87, 223
 Lipoproteins, (104) 183
 Lipoprotein-X, (104) 195
 Longitudinal associations, (104) 173
 Low density lipoprotein, (104) 129
 Low density lipoprotein receptors, (104) 1, 117

 Macrophages, (104) 19
 Malondialdehyde, (104) 213
 Models, (104) 189
 Monocyte chemoattractant protein 1, (104) 61
 Mutations, (104) 117

 Noninsulin-dependent diabetes mellitus, (104) 69
 NonLDL, (104) 159

 Octreotide, (104) 183
 Oxidation, (104) 129

Paraoxonase, (104) 129
Peripheral vascular disease, (104) 87
Phenotype, (104) 87
Plasma viscosity, (104) 173
Platelets, (104) 27
Polymerase chain reaction, (104) 117
Prostacyclin, (104) 27
Protein kinase C, (104) 137

Renal failure, (104) 195

Serum lipids, (104) 153
Smooth muscle cell, (104) 61
Smooth muscle cell proliferation, (104) 79
Statins, (104) 1

Tunisia, (104) 153

Vascular injury, (104) 79
Vascular smooth muscle cells, (104) 95
Vascular smooth muscle cells proliferation, (104) 137
Vasoprin, (104) 79
Very low density lipoprotein remnants, (104) 1
VLDL-apo B, (104) 147
VLDL-composition, (104) 147

Xanthoma, (104) 153

Zucker fa/fa rat, (104) 147